VBI VACCINES INC. (TSE:VBV) Files An 8-K Regulation FD DisclosureItem 7.01 Regulation FD Disclosure.
On July 11, 2017, VBI Vaccines Inc. (the “Company”) issued a press release. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated by reference in this Item 7.01.
The information disclosed under this Item 7.01, including Exhibit 99.1, hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be deemed “filed” with the U.S. Securities and Exchange Commission nor incorporated by reference into any filing made under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit No. | Description |
| 99.1* | Press Release dated July 11, 2017 |
* Furnished herewith
VBI Vaccines Inc/BC ExhibitEX-99.1 2 ex99-1.htm Exhibit 99.1 VBI Vaccines Announces Phase 3 Clinical Program for Sci-B-Vac™ Hepatitis B Vaccine Conference Call and Webcast: Wednesday,…To view the full exhibit click here
About VBI VACCINES INC. (TSE:VBV)
VBI Vaccines Inc. is a development-stage biotechnology company. The Company’s principal products include cytomegalovirus (CMV) Vaccine Candidate, enveloped Virus Like Particle (eVLP) Vaccine Platform and Lipid Particle Vaccine (LPV) Vaccine Platform. The Company is also engaged in the research and development (R and D) activity. The Company’s subsidiaries includes Variation Biotechnologies (US), Inc. (VBI US) and Variation Biotechnologies Inc. (VBI Cda).
